You just read:

Regeneron and Sanofi Announce Cemiplimab (REGN2810) Has Received FDA Breakthrough Therapy Designation for Advanced Cutaneous Squamous Cell Carcinoma

News provided by

Regeneron Pharmaceuticals, Inc.

Sep 08, 2017, 01:00 ET